Skip to content

Exploratory Clinical Study on the Use of Bacteriophage Cocktail Formulations in the Treatment of Multidrug-Resistant Bacterial Infections

Exploratory Clinical Study on the Use of Bacteriophage Cocktail Formulations in the Treatment of Multidrug-Resistant Bacterial Infections

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091725
Enrollment
Unknown
Registered
2024-11-01
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infections, Pulmonary Infections, Superficial Wound Infections, and Deep Abscess Infections

Interventions

Sponsors

Chongqing Red Cross Hospital (People’s Hospital of Jiangbei District)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-90 with multidrug-resistant bacterial infections; 2.(2) The pathogen causing the patient's infection should meet one of the following conditions: 1 The pathogen is pan-resistant to antibiotics; 2 The pathogen is resistant to critically important antibiotics* (refer to the 12 classes of superbugs published by WHO in 2017); 3 The pathogen is sensitive to critically important antibiotics in vitro but treatment with this antibiotic is ineffective or not significantly effective (ineffectiveness is defined as recurrent infections with the same resistant pathogen or the patient's development of antibiotic dependency, being unable to discontinue the medication for two months or more); 4 The use of critically important sensitive antibiotics is restricted (e.g., due to organ toxicity or allergy to the antibiotic); 3.At least one lytic bacteriophage can be isolated; 4.(3) The ability to administer treatment via infection site spraying, topical application, nebulization inhalation, perfusion, local injection, or catheter delivery; 5.(4) The subject or their family has fully read, understood, and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Exclusion Criteria: (1) Bacterial infections that can be effectively controlled by antibiotic treatment; 2.(2) Lack of alternative routes of administration other than intravenous injection; 3.(3) Patients deemed unsuitable for participation in this study by the researcher. Withdrawal Criteria: (1) If the subject requests to withdraw informed consent midway; 4.(2) If bacteriophage treatment causes severe adverse reactions that the researcher deems necessary to terminate the treatment.

Design outcomes

Primary

MeasureTime frame
Phage-typing;

Secondary

MeasureTime frame
Clinical outcomes;

Countries

China

Contacts

Public Contactmingyangwang

Chongqing Red Cross Hospital (People’s Hospital of Jiangbei District)

oolaioo123@outlook.com+86 23 88519116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026